TY - JOUR
T1 - Weekly paclitaxel with intermittent imatinib mesylate (Gleevec®)
T2 - Tolerance and activity in recurrent epithelial ovarian cancer
AU - Safra, Tamar
AU - Andreopoulou, Eleni
AU - Levinson, Benjamin
AU - Borgato, Lucia
AU - Pothuri, Bhavana
AU - Blank, Stephanie
AU - Tiersten, Amy
AU - Boyd, Leslie
AU - Curtin, John
AU - Muggia, Franco
PY - 2010/9
Y1 - 2010/9
N2 - Objective: Imatinib mesylate (IM, Gleevec), a potent PDGF/PDGFR tyrosine kinase inhibitor, affects stroma and vascular endothelial cells. Our study sought to determine the safety and activity of paclitaxel with an intermittent schedule of IM. Materials and Methods: rEOC patients previously treated with platinumlpaclitaxel and ≤2 regimens for recurrence were enrolled. Paclitaxel 80 mg/m2 was given on days 3, 10, 17 every 28 days and oral IM 300 mg bid on days 1-4, 8-11, and 13-18. Results: Between 2007-2009, 14 patients enrolled, 12 were evaluable. Nine patients were on study at 12 weeks. Objective responses (by RECIST and/or CA125) occurred in 4 patients. There were no grade 4, and only four grade 3 toxic events: diarrhea, edema and 2 cases of neutropenia. Early study closure was due to sufficient safety information with preliminary encouraging efficacy results. Conclusion: This weekly paclitaxel regimen with intermittent IM is tolerable with anti-tumor activity, making it suitable as part of future studies.
AB - Objective: Imatinib mesylate (IM, Gleevec), a potent PDGF/PDGFR tyrosine kinase inhibitor, affects stroma and vascular endothelial cells. Our study sought to determine the safety and activity of paclitaxel with an intermittent schedule of IM. Materials and Methods: rEOC patients previously treated with platinumlpaclitaxel and ≤2 regimens for recurrence were enrolled. Paclitaxel 80 mg/m2 was given on days 3, 10, 17 every 28 days and oral IM 300 mg bid on days 1-4, 8-11, and 13-18. Results: Between 2007-2009, 14 patients enrolled, 12 were evaluable. Nine patients were on study at 12 weeks. Objective responses (by RECIST and/or CA125) occurred in 4 patients. There were no grade 4, and only four grade 3 toxic events: diarrhea, edema and 2 cases of neutropenia. Early study closure was due to sufficient safety information with preliminary encouraging efficacy results. Conclusion: This weekly paclitaxel regimen with intermittent IM is tolerable with anti-tumor activity, making it suitable as part of future studies.
KW - Imatinib mesylate
KW - Ovarian cancer
KW - Paclitaxel
UR - http://www.scopus.com/inward/record.url?scp=77958591106&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 20944093
AN - SCOPUS:77958591106
SN - 0250-7005
VL - 30
SP - 3243
EP - 3247
JO - Anticancer Research
JF - Anticancer Research
IS - 9
ER -
